Back to Results

A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) that are Causing Significant Morbidity

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Child to Adult

Type of Study

Treatment

Location

Childrens Hospital Colorado

Principal Investigator
Nicholas Foreman,  MD

Nicholas Foreman, MD

Study ID

Protocol Number: 19-2270

More information available at ClinicalTrials.gov: NCT03962543

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers